Calidi Biotherapeutics Inc

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Calidi Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in stem cell-based platforms to revolutionize oncolytic virotherapies. The company was founded in 2014 and is headquartered in San Diego, CA.

SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results.

Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results

SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting.

Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24.

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24

SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering.

Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering

Calidi Biotherapeutics (NYSEMKT: CLDI ) stock is falling on Tuesday after the clinical stage immuno-oncology company priced a public offering of its shares. The company is selling 15,197,500 shares of CLDI stock for 40 cents per share.

Why Is Calidi Biotherapeutics (CLDI) Stock Down 51% Today?

SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics, Inc. Announces Pricing of Public Offering.

Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering

SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company's Novel Immunotherapies at AACR 2024.

Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company's Novel Immunotherapies at the AACR Annual Meeting 2024

SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results.

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results

SAN DIEGO & LOS ANGELES--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics and City of Hope Announce Funding from CIRM to Advance CLD-101 (NeuroNova) in Ovarian Cancer.

Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer

SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference.

Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference

SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board.

Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board

SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit.

Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit

SAN DIEGO--(BUSINESS WIRE)--Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results.

Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results

SAN DIEGO--(BUSINESS WIRE)--Calidi Biotherapeutics Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at SITC 2023.

Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023)

Calidi Biotherapeutics (NYSE: CLDI ) stock is taking a beating on Wednesday following the clinical-stage biotechnology company's public debut. Calidi Biotherapeutics is making its public debut after completing a special purpose acquisition company (SPAC) merger with First Light Acquisition Group.

Why Is Calidi Biotherapeutics (CLDI) Stock Down 36% Today?

First Light Acquisition Group

Business combination transaction with First Light Acquisition Group, a special purpose acquisition company, completed on September 12, 2023

Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

Business combination transaction with Calidi Biotherapeutics anticipated to be completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics from transaction will total approximately $28 million, including funds held in First Light Acquisition Group's trust account before deducting transaction expenses and debt repayments In addition, Calidi secured a forward purchase agreement for up to $10 million with a consortium including Meteora Capital LLC, Great Point Capital LLC, and Funicular Funds, LP Listed company to be named Calidi Biotherapeutics, Inc. Common stock and warrants approved for listing on the New York Stock Exchange American under the ticker symbols “CLDI” and “CLDI WS,” respectively; expected to begin trading on September 13, 2023 NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (NYSE: FLAG) (“FLAG”) today announced that it anticipates completing its business combination with Calidi Biotherapeutics on September 12, 2023.

First Light Acquisition Group Announces NYSE Approval for Listing of Business Combination with Calidi Biotherapeutics and Additional New Capital Commitments

News for Calidi Biotherapeutics Inc Stock (CLDI)